COG-AALL1821
Phase II
OPEN TO ACCRUAL
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
COG-AREN1921
Phase II
OPEN TO ACCRUAL *
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
IIT-BURKE-VENETOCLAX-EPIGENETI
Phase I
OPEN TO ACCRUAL
A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients with Relapsed and Refractory Acute Myeloid Leukemia
MSKCC-23-278
Phase II
OPEN TO ACCRUAL
Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic Anemia
PBMTC-ONC1401
Phase II
OPEN TO ACCRUAL
The Role of KIR-Favorably Mismatched Haploidentical Transplantation and KIR-Polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
P-HEMONC-CUIMC-23-040
Phase II
OPEN TO ACCRUAL *
Phase 2 Study BRIDGING PRE-TRANSPLANT INFLAMMATORY DAMPENING for PRIMARY IMMUNE REGULATORY DISORDERS (BRIDGE Trial)
PTCTC-ONC2301
Phase I/II
OPEN TO ACCRUAL *
A Phase 1b/2 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T-ALL/T-LLy) (ALLO-T-DART)
SPOC-2012-001
Phase I
OPEN TO ACCRUAL
Phase 1 Dose-Escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors